WallStSmart

Paychex Inc (PAYX)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Paychex Inc generates 1433% more annual revenue ($3.97B vs $258.90M). PAYX leads profitability with a 26.6% profit margin vs -15.5%. PAYX earns a higher WallStSmart Score of 65/100 (B-).

PAYX

Strong Buy

65

out of 100

Grade: B-

Growth: 6.7Profit: 9.5Value: 4.0Quality: 4.0
Piotroski: 3/9Altman Z: 1.32

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PAYXSignificantly Overvalued (-36.3%)

Margin of Safety

-36.3%

Fair Value

$69.56

Current Price

$92.63

$23.07 premium

UndervaluedFair: $69.56Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PAYX4 strengths · Avg: 9.3/10
Return on EquityProfitability
40.3%10/10

Every $100 of equity generates 40 in profit

Operating MarginProfitability
44.4%10/10

Strong operational efficiency at 44.4%

Profit MarginProfitability
26.6%9/10

Keeps 27 of every $100 in revenue as profit

Revenue GrowthGrowth
19.9%8/10

19.9% revenue growth

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

PAYX4 concerns · Avg: 3.5/10
PEG RatioValuation
1.744/10

Expensive relative to growth rate

Price/BookValuation
8.3x4/10

Trading at 8.3x book value

Debt/EquityHealth
1.303/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : PAYX

The strongest argument for PAYX centers on Return on Equity, Operating Margin, Profit Margin. Profitability is solid with margins at 26.6% and operating margin at 44.4%. Revenue growth of 19.9% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : PAYX

The primary concerns for PAYX are PEG Ratio, Price/Book, Debt/Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

PAYX profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PAYX scores higher overall (65/100 vs 41/100), backed by strong 26.6% margins and 19.9% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Paychex Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Paychex, Inc. is an American provider of human resource, payroll, and benefits outsourcing services for small- to medium-sized businesses.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?